- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE to sell R2’s CAD workstations
R2 Technology landed a big fish this month when the developer of mammography computer-aided diagnosis (CAD) workstations signed an exclusive OEM supply deal with GE Medical Systems of Milwaukee. GE has agreed to bundle R2's ImageChecker workstation with
R2 Technology landed a big fish this month when the developer of mammography computer-aided diagnosis (CAD) workstations signed an exclusive OEM supply deal with GE Medical Systems of Milwaukee. GE has agreed to bundle R2's ImageChecker workstation with its full-field digital mammography systems under development, and sell both products to customers as part of a complete package.
R2 of Los Altos Hills, CA, developed ImageChecker to provide a backup to mammographers reading digitized exams by flagging suspicious areas. R2 began selling ImageChecker in Europe in 1997, and filed a premarket approval (PMA) application with the Food and Drug Administration later that year.
ImageChecker would complement GE's work in digital mammography. Digital x-ray data collected by GE's digital systems could be fed into ImageChecker for analysis. GE's healthy market share in mammography would ensure a large potential market for ImageChecker.
The agreement does not cover the use of ImageChecker with digitized mammography film, leaving R2 open to securing new OEM relationships for that configuration of its product. R2 at one point had been in discussions with Imation over a distribution deal for ImageChecker, but those talks never developed further (SCAN Special Report 12/97).
R2 officials declined to comment on the GE relationship, as the company is still in a quiet period related to its pending initial public offering. The launch of the IPO is contingent on market conditions, according to a source close to the company.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
